CA
NZ
UK
AU
IND
US
On October 6, 2026 Crescent Biopharma (NASDAQ:CBIO) announced options to buy an aggregate 81,525 ordinary shares for six non-executive employees, approved October 5. The exercise price of USD 13.94 equals the October 5 closing price. The options run 10 years under the 2025 Employment …
Evolent Health (NYSE:EVH) rose about 6.1% to USD 4.07 on October 7, 2026, according to published market data. Claritev (NYSE:CTEV) gained 2.5%. Phreesia (NYSE:PHR) added 0.2%, a 1.4% median for the pair, so the move was larger than the group. We found no company …
Cencora's 50-day moving average of USD 317.90 has moved above its 200-day moving average of USD 317.82, completing a golden cross with a gap of 0.027 percent, a narrow but technically confirmed crossover. Shares recently traded at USD 319.69, up 1.05 percent, placing the …
Savara is approaching the FDA's November 22, 2026 target action date for MOLBREEVI, its inhaled therapy for autoimmune pulmonary alveolar proteinosis, under Priority Review following a three-month extension granted earlier in 2026. The drug carries Fast Track, Breakthrough Therapy andOrphan Drugdesignations, and Savara (NASDAQ:SVRA) …
Published market data show Picard Medical (NYSEAMERICAN:PMI) rising about 13.3% to USD 9.90, versus the 15.3% in some early reports. The exact session is uncertain: another quote page showed USD 8.67 at 1:47 p.m. ET on October 7, 2026, so the USD 9.90 level …
Progyny (NASDAQ:PGNY) issued a company release on October 7, 2026 titled as selling season pacing to a record level. It said 1.2 million new covered lives are expected from commitments to date and anticipated remaining decisions, with launches through the first half of 2027. …
Savara (NASDAQ:SVRA) rose about 7.6% to USD 5.01 on October 7, 2026, according to published market data, with some quote pages showing a gain near 8.0% around midday. Early reports tied the move to Citizens reiterating its rating on the Molbreevi launch outlook, which …
Zenas BioPharma (NASDAQ:ZBIO) rose USD 1.55 to USD 28.43 on October 7, 2026, published market data show. That is about 5.8% by simple arithmetic, while the headline says 5.5%. The company release of October 6, 2026 announced a virtual R&D event on October 27 …
● Caribou Biosciences tumbled to about $0.61 after hours.
Apimeds Pharmaceuticals (NYSE American:APUS) soared on Tuesday, October 6, trading at about $7.00, with its market value put at about $6.9 million. No company announcement explaining the move was found, and no press release, filing or clinical update tied to the session turned up …
Please wait processing your request...